Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | HRH1 | P35367 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | NOS2 | P35228 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31366495 | 1.00 | ALDH1A1 (0.67) | ALDH1A1HTTCYP1A2CYP2C19LMNA | |
| SCHEMBL8081475 | 0.92 | MAPT (0.65) | ALDH1A1HTTCYP1A2CYP2C19LMNA | |
| SCHEMBL1536676 | 0.89 | ALDH1A1 (0.69) | ALDH1A1HTTCYP1A2CYP2C19LMNA | |
| SCHEMBL5121593 | 0.86 | MAPT (0.62) | ALDH1A1HTTCYP1A2CYP2C19LMNA | |
| SCHEMBL14740763 | 0.86 | MAPT (0.66) | ALDH1A1HTTCYP1A2CYP2C19LMNA | |
| SCHEMBL1820102 | 0.86 | POLB (0.71) | ALDH1A1HTTCYP1A2CYP2C19LMNA | |
| SCHEMBL29379915 | 0.86 | MAPT (0.66) | ALDH1A1HTTCYP1A2CYP2C19LMNA | |
| SCHEMBL10952466 | 0.86 | HTT (0.58) | ALDH1A1HTTCYP1A2CYP2C19LMNA | |
| SCHEMBL31366556 | 0.86 | HTT (0.58) | ALDH1A1HTTCYP1A2CYP2C19LMNA | |
| SCHEMBL3480945 | 0.83 | ALDH1A1 (0.71) | ALDH1A1HTTCYP1A2CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110606839-B | Green synthesis method of polysubstituted quinazoline derivative | 南方医科大学 | 2021-10-08 | — | — | CN | claimed |
| US-20250197360-A1 | NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE | BARUCH S. BLUMBERG INSTITUTE | 2025-06-19 | — | — | US | disclosed |
| WO-2023172726-A1 | NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE | BARUCH S. BLUMBERG INSTITUTE (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023172726-A1 | NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE | BARUCH S. BLUMBERG INSTITUTE (US) | 2023-09-14 | — | — | WO | disclosed |
| US-11021448-B2 | 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases | HOFFMANN-LA ROCHE INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | NOVARTIS AG (CH) | 2021-05-18 | — | — | US | disclosed |
| EP-3722277-A2 | 3'END CAPS FOR RNA-INTERFERRING AGENTS FOR USE IN RNA | Novartis AG (CH) | 2020-10-14 | — | — | EP | disclosed |
| US-10519446-B2 | Organic compounds to treat hepatitis B virus | NOVARTIS AG (CH) | 2019-12-31 | — | — | US | disclosed |
| EP-3535253-A1 | 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES | H. Hoffnabb-La Roche Ag (CH) | 2019-09-11 | — | — | EP | disclosed |
| US-20190256478-A1 | 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | disclosed |
| EP-1392663-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2004-03-03 | — | — | EP | disclosed |
| US-6596773-B2 | Central nervous system disorders | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | disclosed |
| WO-2002098865-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2002-12-12 | — | — | WO | disclosed |
| US-20020111367-A1 | Phenyl substituted pyridine and benzene derivatives | BOS MICHAEL (CA) | 2002-08-15 | — | — | US | disclosed |
| US-6407111-B1 | SUBSTANCE P OR NEUROKININ 1 ANTAGONISTS; ANTIINFLAMMATORY, ANTIDEPRESSANT, ANTIARTHRITIC, AND ANTIASTHMATIC AGENTS; PARKINSON*S DISEASE, INFLAMMATORY BOWEL DISEASE, CENTRAL NERVOUS SYSTEM AND RHEUMATIC DISORDERS | HOFFMANN-LA ROCHE INC. | 2002-06-18 | — | — | US | disclosed |
| EP-1157006-A2 | PHENYL- AND PYRIDINYL DERIVATIVES AS NEUROKININ 1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000050398-A2 | PHENYL- AND PYRIDINYL DERIVATIVES AS NEUROKININ 1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-31 | — | — | WO | disclosed |
| US-4898874-A | Acetic acid derivatives of 3-aryl-2,1-benzisoxazole and esters and amides thereof | A. H. ROBINS COMPANY, INC. (US) | 1990-02-06 | — | — | US | disclosed |
| EP-0260924-A1 | Antiinflammatory derivatives of 3-aryl-2,1-benzisoxazole | A.H. ROBINS COMPANY, INCORPORATED (US) | 1988-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111367-A1 | Phenyl substituted pyridine and benzene derivatives | BDKRB1, BAK1, PBK | ALDH1A1 754/4885HTT 4351/4885CYP1A2 920/4885 |
| US-11021448-B2 | 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases | CHRM1, CHRM2, CHRM4 | ALDH1A1 1148/4885HTT 929/4885CYP1A2 184/4885 |
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | RNGTT, NSUN2, NSUN3 | ALDH1A1 4223/4885HTT 2524/4885CYP1A2 4882/4885 |
| US-20190256478-A1 | 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES | CHRM1, CHRM2, CHRM4 | ALDH1A1 1148/4885HTT 929/4885CYP1A2 184/4885 |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | PDE7A, PDE3B, PDE3A | ALDH1A1 395/4885HTT 4305/4885CYP1A2 155/4885 |
| US-20250197360-A1 | NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE | CUL4B, BRD4, CUL4A | ALDH1A1 4616/4885HTT 2301/4885CYP1A2 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.